---
type: "NewsArticle"
title: "FDA warns against supplement-grade glutathione in injectable compounds"
description: "FDA reported adverse events in at least 30 patients after compounded IV glutathione and warned against using supplement-grade material for injections."
resource: "https://nootropikler.com/news/fda-glutathione-injection-quality-alert"
tags: ["brain-health", "evidence-limits", "safety"]
timestamp: 2026-10-04T23:57:49Z
language: "en"
---

# FDA warns against supplement-grade glutathione in injectable compounds

FDA reported adverse events in at least 30 patients after compounded IV glutathione and warned against using supplement-grade material for injections.

Author: Nootropik News Editorial Team
Published: 2026-10-04T23:57:49Z
Update: 2026-10-04T23:57:49Z
News/source date: 2026-08-27
Production: AI-assisted sourced summary and translation; no independent medical expert review is claimed.

## What happened

On August 27, 2026, FDA reported adverse events in at least 30 patients after intravenous glutathione, alone or with other ingredients. Different compounding pharmacies had sourced dietary-supplement-grade glutathione from Medisca lot 229536. Two Texas pharmacies recalled injectable products after finding elevated endotoxin. Reported symptoms included fever, chills, dizziness and sepsis-like reactions, with some hospitalizations. The agency described an ongoing investigation, rather than a completed estimate of every exposed patient’s risk.

## Why it matters

The central issue is manufacturing quality for the intended route of administration. A material supplied for dietary use is not automatically appropriate for injection; contaminants tolerated or handled differently through one route can pose different problems through another. FDA said Medisca warned U.S. customers on August 20 against using this grade for injectables. It also stressed that testing alone cannot replace quality controls across ingredient sourcing and compounding.

## Scope and limitations

FDA urged affected compounders to contact customers and discontinue the implicated IV products. The alert cited earlier communication in 2019, showing this was a recurring quality concern. It did not investigate cognitive enhancement, establish the same risk for all oral glutathione products, or report that every possible endotoxin symptom occurred in this cluster. Readers should keep the lot, route and formulation distinctions intact rather than translate an injectable-product alert into a claim about every supplement bearing the ingredient name.

## Sources

- [FDA reminds compounders not to use dietary supplement grade glutathione for injectables](https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables) — 2026-08-27
